High Stakes - The Financial Conduct Authority issues preliminary guidance for cannabis companies looking to list on the London Stock Exchange
On 18 September, the Financial Conduct Authority (FCA) set out its approach in assessing applications by cannabis-related companies for listing in the UK. Although this guidance is high-level for now, the FCA confirm that a consultation on their approach to this topic “will follow in due course”.
The FCA makes the point that the law surrounding overseas medical cannabis businesses is largely a complex area, with the risk of proceeds from such businesses constituting criminal property under the Proceeds of Crime Act 2002 (POCA) remaining a paramount issue. The review comes following the legalisation of medical cannabis in 2018, where specialist doctors can now prescribe patients medicinal cannabis.
Up until now, investors into the UK would have largely found difficulties in investing in this sector because of POCA’s deliberately wide definition of ‘criminal property’. Under POCA, the proceeds of any activity conducted overseas will be deemed as criminal property if that activity is illegal in the UK, even if it is legal or licenced in the country in question. This poses an issue for UK companies seeking to invest into, or acquire, foreign companies that operate a cannabis-related business as the payment of dividends upwards could breach POCA. The FCA helpfully categorise cannabis companies into three categories:
- Recreational cannabis companies – as recreational cannabis is illegal in the UK, these companies will not be admitted to the Official List, regardless of whether it is legal or licenced in its own jurisdiction.
- UK-based medical cannabis companies – these companies can be admitted to the Main Market as long as they have the appropriate Home Office licences in place.
- Overseas-licenced medical cannabis companies – these companies will be assessed on a case-by-case basis. In order to be admitted to the Main Market, the FCA must be satisfied that POCA does not apply and the usual criteria for listing is met.
In summary, companies that are fully licenced for all their activities in the UK are now able to float in the UK. This also means certain foreign operators that have a medical equivalence are also eligible to be admitted to the Main Market, subject to a POCA review by the FCA.
With the FCA citing that this guidance is in response to various queries, there is clearly an appetite from cannabis-related companies to apply for listing and it may be the case that there are already companies with draft prospectuses almost ready to apply very soon.
Although this is promising news for companies already operating in this space, it is unlikely that we will see an immediate influx of listings for medical cannabis companies. With an emphasis on medical cannabis, these companies, and investors, will need to have a very good understanding as to how the regulatory framework surrounding medical cannabis works in practice. It is also not entirely clear where the FCA stands with ‘over the counter’ or wellness companies dealing with cannabis.
Steps will have to be taken by a cannabis-related company to establish whether it can be admitted to the Main Market, primarily through a review of its licences. Overseas companies will have to consider further steps, with a review of its foreign licenses and an analysis that its operations would remain legal if carried out in the UK having to be undertaken.
It also remains to be seen how the FCA will approach the POCA review. In any case, we consider that it would remain prudent for a company seeking to list on the Main Market to obtain Counsel’s opinion on the legality (or otherwise) of their activities and it may be the case that the FCA are happy to rely on such opinions.
It will also be interesting to see the approach of the AIM regulation team of the London Stock Exchange to any proposed cannabis-related listings and whether they follow the FCA’s approach.
Our expertise in the relevant areas of law, including regulatory, capital markets and healthcare, as well as our network of international firms, means we as a firm are well positioned to assist those looking to act on this new guidance from the FCA.
Charity Training: Digital Transformation in the Charity Sector
We would be delighted if you could join us for the second session in our new series of bite-size webinars for charities.
Charity Training: Brand Protection
We would be delighted if you could join us for the first in our new series of bite-size webinars for charities.
The UK’s New Skilled Worker & Intra-Company Visa Routes: a closer look
Taking a closer look at the UK’s new visas to assist UK businesses.
Practicalities in Cladding Claims
Insight into Issues with Cladding Claims
EWS1 Forms - the latest episode
RICS have now published their highly anticipated guidance on when EWS1 forms will be required.
Q&A: Am I insured for COVID-19?
Laura Bushaway writes for Estates Gazette on a recent claim under the “disease clause” of business interruption policy.
Focus Antitrust - 7 April 2021
This week's competition update.
No ticket, no merger: Viagogo and StubHub are one step closer to merging but must satisfy the CMA’s conditions
The £3.2bn acquisition of online ticketing company Stubhub by one of its competitors, Viagogo is one step closer to being finalised.
The Purpose Podcast: Corporate purpose
Simon Ridpath discusses corporate purpose and the rise of environmental, social and governance (ESG) issues in “The Purpose Podcast”
Client alert: Construction under competition law spotlight
We outline the three investigations which have either recently concluded or are ongoing together with what this means for businesses.
Focus Antitrust - 31 March 2021
This week's competition update.
Looking beyond the benefitted land: confirmation that an objector’s wider property may be considered in applications to discharge/modify restrictive covenants
Read our recent case study on applicants who were prevented from developing a new house due to a restrictive covenant covering their land.
Further extension of coronavirus restrictions affecting residential properties: Where are we now?
The extension will be implemented from and including 31 March 2021 by the Coronavirus Act 2020.
Knight Frank Wealth Report: The Global Perspective on Prime Property & Investment
Knight Frank partners joined Charles Russell Speechlys for a virtual panel-led discussion on the Knight Frank Wealth Report
Case Study: One Blackfriars Limited
An informative and positive judgment for administrators selling high-value property in distressed and complex scenarios.
Keeping Up With Construction: Handover at Practical Completion - Practical Pointers
Practical tips for the handover of a successful project.
Charles Russell Speechlys advises on Trident Royalties’ US$28m Placing
Trident Royalties plc is a growth-focused mining royalty and streaming company.
Commercial rent arrears: what are the latest restrictions on landlords’ remedies this quarter day?
What you need to know for this Quarter Day.
The Corporate team's involvement in Fishawack Health’s acquisition of PRMA featured in Yahoo! Finance USA, Markets Insider and Morning Star
Martin Wright and the Corporate team provided legal support on the acquisition of PRMA Consulting.
Jessica Arrol quoted by Real Deals on the implementation of SFDR
SFDR aims to remove greenwashing and promote transparency in reporting ESG, but GPs and LPs are experiencing its flaws.